TY - JOUR
T1 - Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics
T2 - A randomized controlled trial
AU - Berg, Karina M.
AU - Litwin, Alain
AU - Li, Xuan
AU - Heo, Moonseong
AU - Arnsten, Julia H.
PY - 2011/1/15
Y1 - 2011/1/15
N2 - Objective: To determine if directly observed antiretroviral therapy (DOT) is more efficacious than self-administered therapy for improving adherence and reducing HIV viral load (VL) among methadone-maintained opioid users. Design: Two-group randomized trial. Setting: Twelve methadone maintenance clinics with on-site HIV care in the Bronx, New York. Participants: HIV-infected adults prescribed combination antiretroviral therapy. Main outcomes measures: Between group differences at four assessment points from baseline to week 24 in: (1) antiretroviral adherence measured by pill count, (2) VL, and (3) proportion with undetectable VL (<75. copies/ml). Results: Between June 2004 and August 2007, we enrolled 77 participants. Adherence in the DOT group was higher than in the control group at all post-baseline assessment points; by week 24 mean DOT adherence was 86% compared to 56% in the control group (p< 0.0001). Group differences in mean adherence remained significant after stratifying by baseline VL (detectable versus undetectable). In addition, during the 24-week intervention, the proportion of DOT participants with undetectable VL increased from 51% to 71%. Conclusions: Among HIV-infected opioid users, antiretroviral DOT administered in methadone clinics was efficacious for improving adherence and decreasing VL, and these improvements were maintained over a 24-week period. DOT should be more widely available to methadone patients.
AB - Objective: To determine if directly observed antiretroviral therapy (DOT) is more efficacious than self-administered therapy for improving adherence and reducing HIV viral load (VL) among methadone-maintained opioid users. Design: Two-group randomized trial. Setting: Twelve methadone maintenance clinics with on-site HIV care in the Bronx, New York. Participants: HIV-infected adults prescribed combination antiretroviral therapy. Main outcomes measures: Between group differences at four assessment points from baseline to week 24 in: (1) antiretroviral adherence measured by pill count, (2) VL, and (3) proportion with undetectable VL (<75. copies/ml). Results: Between June 2004 and August 2007, we enrolled 77 participants. Adherence in the DOT group was higher than in the control group at all post-baseline assessment points; by week 24 mean DOT adherence was 86% compared to 56% in the control group (p< 0.0001). Group differences in mean adherence remained significant after stratifying by baseline VL (detectable versus undetectable). In addition, during the 24-week intervention, the proportion of DOT participants with undetectable VL increased from 51% to 71%. Conclusions: Among HIV-infected opioid users, antiretroviral DOT administered in methadone clinics was efficacious for improving adherence and decreasing VL, and these improvements were maintained over a 24-week period. DOT should be more widely available to methadone patients.
KW - Directly observed therapy
KW - HIV
KW - Medication adherence
KW - Methadone
KW - Randomized trial
UR - http://www.scopus.com/inward/record.url?scp=78651494300&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78651494300&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2010.07.025
DO - 10.1016/j.drugalcdep.2010.07.025
M3 - Article
C2 - 20832196
AN - SCOPUS:78651494300
SN - 0376-8716
VL - 113
SP - 192
EP - 199
JO - Drug and Alcohol Dependence
JF - Drug and Alcohol Dependence
IS - 2-3
ER -